Myomo Inc
$ 0.65
-5.24%
24 Feb - close price
- Market Cap 25,167,600 USD
- Current Price $ 0.65
- High / Low $ 0.71 / 0.64
- Stock P/E N/A
- Book Value 0.38
- EPS -0.28
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -1.00 %
- 52 Week High 6.30
- 52 Week Low 0.64
About
Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$5.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-06 | 2025-03-05 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-03-07 | 2023-11-07 | 2023-08-09 | 2023-05-10 | 2023-03-13 |
| Reported EPS | -0.09 | -0.12 | -0.08 | -0.01 | -0.03 | -0.03 | -0.1 | -0.07 | -0.06 | -0.04 | -0.11 | -0.29 |
| Estimated EPS | -0.11 | -0.1 | -0.1 | -0.0233 | -0.04 | -0.07 | -0.1 | -0.06 | -0.09 | -0.03 | -0.13 | -0.42 |
| Surprise | 0.02 | -0.02 | 0.02 | 0.0133 | 0.01 | 0.04 | 0 | -0.01 | 0.03 | -0.01 | 0.02 | 0.13 |
| Surprise Percentage | 18.1818% | -20% | 20% | 57.0815% | 25% | 57.1429% | 0% | -16.6667% | 33.3333% | -33.3333% | 15.3846% | 30.9524% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYO
2026-02-18 00:28:03
Rosalind Advisors, Inc. significantly increased its stake in Myomo Inc. by adding over 3.8 million shares on December 31, 2025. This move boosts Rosalind Advisors' total holding to over 7.6 million shares and reflects its confidence in the medical robotics company's long-term potential, despite Myomo Inc.'s current financial challenges and status as a possible value trap. The investment firm, known for value investing, now holds 9.90% of its Myomo Inc. position, impacting its overall portfolio by 1.18%.
2025-12-17 07:11:34
Myomo, Inc.'s CEO, Paul Gudonis, and CFO, David Henry, have chosen to reduce their 2026 base salaries by 10% in exchange for restricted stock units (RSUs). This decision was approved by the company's Compensation Committee and is detailed in a recent SEC filing. The RSUs will be granted in quarterly installments starting January 12, 2026, and will vest fully three months after each grant date, provided the executive remains employed.
2025-12-16 07:02:00
Myomo, Inc.'s CEO, Paul Gudonis, and CFO, David Henry, have elected to reduce their 2026 base salaries by 10% in exchange for restricted stock units (RSUs). This decision, approved by the Compensation Committee, will see them receive RSUs valued at 115% of the foregone salary, vesting quarterly starting January 12, 2026. This move follows a positive third-quarter 2025 earnings report where the company exceeded revenue and EPS expectations.
2025-11-24 10:09:50
Director Thomas Aloysius Crowley Jr. recently purchased Myomo, INC. (NYSE: MYO) shares totaling $3,232 in two transactions. This comes as Myomo's stock is near its 52-week low, despite analysts maintaining a "Strong Buy" consensus and the company reporting better-than-expected Q3 2025 earnings and revenue. The purchases signal potential insider confidence amid the stock's significant decline over the past year.
2025-11-14 21:01:00
Rosalind Advisors, Inc. significantly increased its stake in Myomo Inc. by acquiring 3,958,258 additional shares, bringing its total holdings to over 7.5 million shares. This move by the prominent investment firm, which focuses on medical and biotechnology, highlights its confidence in Myomo Inc.'s long-term potential despite the medical robotics company facing significant financial challenges and a substantial decline in stock value since its IPO. Value investors are cautioned to weigh the inherent risks against potential rewards, considering Myomo Inc.'s current financial metrics.
2025-11-14 08:09:39
Myomo Inc. announced an increase in Q3 2025 revenue to $10.1 million, up from $9.2 million year-over-year, driven by strong sales in both direct-to-patient and clinical provider channels. Despite this growth, the company reported a net loss of $3.7 million due to increased operating expenses, particularly in research and development and selling and marketing. Myomo's management aims to achieve positive cash flow and sustain operations through strategic financing and market expansion, while facing challenges in reimbursement and competitive pressures.
